Long Ideas - Halozyme Therapeutics (NASDAQ:HALO) announced that it has licensed the use of its technology platform to Pfizer Inc. (NYSE:PFE) to develop Pfizer’s biologics with Halozyme’s Enhanze … Continue Reading
Read NowLong Ideas - Orexigen Therapeutics (OREX) will be the last of three leading weight-loss drug developers to enter the large potential market for new obesity treatments, and biotech … Continue Reading
Read NowMost Popular - Abbot Labs recorded the first sale of Amitiza in Japan, resulting in a $15M milestone payment to Sucampo on Tuesday. Nevertheless, the thinly-traded equity reacted … Continue Reading
Read NowLong Ideas - Acadia Pharmaceuticals (NASDAQ:ACAD) announced on Wednesday morning a private equity financing to sell 19 million shares of common stock at $4.43 per share, plus warrants to purchase … Continue Reading
Read NowMost Popular - Amarin plans to “go it alone” with its Vascepa launch. Without a large pharma partnership or, better yet, an acquirer, we don’t expect investors to … Continue Reading
Read NowMost Popular - Coincident with securing $100M in non-equity financing, Amarin Corp. (AMRN) announced after the close on Thursday that it will begin hiring a sales force to … Continue Reading
Read NowMost Popular - Many investors who choose to invest in the sector choose, for better to worse, to focus only on the clinical and medicinal aspects of these … Continue Reading
Read Now